The Indian Pharmaceutical Market (IPM) has clocked a growth of 9.5 per cent during March 2018 to Rs. 10,029 crore compared to 7.1 per cent in February 2018. As per the AIOCD AWACS report, the volumes have posted a positive growth, however price component is dragging the market. The NLEM 2013 containing molecules market showed growth at 8.7 per cent whereas the non NLEM market grew at 9.8 per cent resulting in an overall growth of 9.5 per cent. FDC related market showed growth of 17.3 per cent while the non FDC market showed a growth of 9.4 per cent, while the single molecules grew at 8.5 per cent for the months March 2018.
MNCs are growing at double digit rate at 11.2 per cent, while Indian companies are growing comparatively slower at 9.1 per cent. Amongst the top 60 MNCs, Danone was the fastest growing at 20.3 per cent followed by Boehringer Ingelheim growing at 20.2 per cent and Allergan which grew a 19 per cent during March 2018. In the non-NLEM category Indian companies showed a growth of 9.2 per cent whereas MNCs grew at 12.3 per cent.
From therapy perspective 19 therapies are showing a positive growth during March 2018. Respiratory market posted a double growth of 20.1 per cent, gastro intestinal showed an improved growth at 9.8 per cent and pin and analgesic market showed a double digit growth of 10.2 per cent. Anti-diabetic market has slowed down at 7.8 per cent and cardiac at 7.1 per cent, Neuro/CNS showed at growth of 7.8 per cent. Anti infectives growing at a double digit rate of 10.7 per cent while VMS market is growing at 7.7 per cent. Derma achieved growth of 7.7 per cent.
Total 29 regions have posted positive growth for month of March 2018. Madhya Pradesh market grew the highest at 23.36 per cent followed by UP East growing at 23.02 per cent and Haryana at 17.12 per cent.
Amongst the top 10 corporate, Lupin has the highest growth at 16.9 per cent followed by Alkem at 14.8 per cent and Abbott at 13.7 per cent. Among the top 50 companies, 46 companies showing positive growth of IPM. Hetero has the highest growth of 38.3 per cent followed by Win Medicare growth at 26.9 per cent and Franco Indian at 23.9 per cent. Sun Portfolio has shown a growth of 10.1 per cent, while Ranbaxy has posted an improved growth of 8.6 per cent.
During the last 36 months, total 20 companies were launched and of this one company crossed revenue of Rs. 10 crore in March 2018. amoxycillin plus clavulanic acid market is showing a recovery at 14 per cent monthly growth at Rs. 158.7 crore. Glimepiride plus metformin market is showing a single digit growth of 2 per cent at Rs. 168.4 crore. azilsarta plain market is now valued at Rs. 64.5 crore on MAT basis and sofosbuvir and its combination market has reached at Rs. 602.4 crore. The luliconazole market is worth Rs. 274.3 crore, while tenegliptin and its combinations have crossed Rs. 646.2 crore mark. Paracetamol plan market achieved double digit growth of 27.9 per cent on monthly basis. However, plain atorvastatin market declined by 1.5 per cent.
Spsmoproxyvon plus brand has overtken Mixtard in monthly sales by posting Rs. 40 crore while Mixtard has registered sales of Rs. 30 crore. Clycomet GP reached at Rs. 35 crore, Lantus as at 31 crore and Galvus met at Rs 33 crore. Liv 52 touched to Rs. 26 crore and Janumet at Rs. 31 crore during March 2018. Within the VMS category there have been 7 brands launched for the months of March 2018 and that in cardiac there have been 13 new brands. Within derma and gastro categories, 7 new product each were launched.